EGFR and non-small cell lung carcinoma: A study by Helena et al. showed that in advanced NSCLC patients with EGFR mutation who had not received EGFR‐TKIs and/or VEGFR inhibitors, the 12‐month rate of PFS was 76% and mPFS was 19 months when receiving osimertinib combined with bevacizumab.18